So when we sold to NVS the only potential revenue stream lost was TIP correct. We still receive the full value of the agreements on Cipro and NKTR-061? Also, what is the status of NKTR-063 and by my understanding we have not partnered it yet. Just trying to clarify the inhalation side of the business. Exactly what did NVS get for the 118 mil? To the CC was anything mentioned about the breast cancer trial for NKTR-102 and timeline on NKTR-105 phase I update? How come nobody ever asks in the call about the Neulasta agreement? Sorry about the questions just haven't had time to listen to the call.